The Role of Xerostomia in Burning Mouth Syndrome: Case - Control Study
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
Objectives: to evaluate xerostomia and salivary flow in patients with burning mouth syndrome
(BMS) treated with amitriptyline before and after the use of antixerostomic topical
medication.
Methods: In this case-control double-blinded study, we enrolled 38 patients with BMS
diagnosed according to the (IASP). The subjects were randomly divided into two groups: Study
Group: 19 patients whom received topical medication of urea 10% and Control Group: 19
patients whom received placebo to apply at the oral cavity 3-4 times per day, during three
months. The patients were evaluated before and after the above treatment. Finally, data were
statistically analyzed.
It is know that BMS is eventually associated to reduced salivary flow (Cho et al.,2010; Kho
et al., 2010; Marino et al., 2010) and to abnormal salivary composition (increasing
concentrations of K+, Na+, Cl-, Ca+2, IgA, amylase) (Patton et al., 2007). Even in the
absence of hyposalivation, patients may complain of xerostomia and dry mouth (Cho et
al.,2010; Kho et al., 2010; Marino et al., 2010; Thomson, 2005). These patients also have
several sensory losses even in taste and smell function, recently described (Siqueira et al.,
2006a; Siqueira et al., 2006b; Siviero et al., 2011).